 PRINCETON, N.J., Nov. 30, 2020 GLOBE NEWSWIRE -- Agile Therapeutics, Inc. Nasdaq: AGRX, a womens healthcare company, today announced that Contraception, an international, peer-reviewed, reproductive health journal, published the primary safety, efficacy, and tolerability results from the Phase 3 SECURE study evaluating Twirla levonorgestrel and ethinyl estradiol transdermal system. The results have been published online in Contraception and will also appear in a future print edition of the journal. 